Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations

被引：0
|
作者：
Cho, B. C. [1 ]
Lu, S. [2 ]
Lee, M. A. [3 ]
Song, Z. [4 ]
Park, J. J. W. [5 ]
Lim, S. M. [6 ]
Li, Z. [2 ]
Zhao, J. [7 ]
Richardson, G. [8 ]
Zhang, Y. [9 ]
Zhang, J. [10 ,12 ]
Liu, A. [11 ]
Chen, C. [12 ]
Wang, J. [12 ]
Chen, J. [12 ]
Wang, A. [12 ]
Zhang, J. [10 ,12 ]
Chen, Z. G. [12 ]
Mok, T. S. K. [13 ]
Johnson, M. L. [14 ]
机构：
[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China
[3] Catholic Univ Korea, Internal Med Dept, Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea
[4] Zhejiang Canc Hosp, Phase Clin Trial Ward 1, Hangzhou, Peoples R China
[5] Macquarie Univ, Fac Med Hlth & Human Sci, Biomed Sci Dept, Sydney, NSW, Australia
[6] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[7] Beijing Canc Hosp, Dept Med Oncol, Beijing, Peoples R China
[8] Cabrini Malvern Hosp, Oncol Clin Victoria, Med Oncol, Malvern, Vic, Australia
[9] Harbin Med Univ, Canc Hosp, GI Oncol, Harbin, Peoples R China
[10] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Oncol, Shanghai, Peoples R China
[11] Nanchang Univ, Affiliated Hosp 2, Med Oncol, Nanchang, Jiangxi, Peoples R China
[12] D3 Bio, Clin Dev Dept, Shanghai, Peoples R China
[13] Prince Wales Hosp, Li Ka Shing Specialist Clin, Clin Oncol Dept, Hong Kong, Peoples R China
[14] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.682
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
615MO
引用
收藏
页码：S493 / S493
页数：1
相关论文
共 50 条
  • [41] D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
    Zhang, Jing
    Lim, Sun Min
    Yu, Mi Ra
    Chen, Cheng
    Wang, Jia
    Wang, Wenqian
    Rui, Haopeng
    Lu, Jingtao
    Lu, Shun
    Mok, Tony
    Chen, Zhi Jian
    Cho, Byoung Chul
    CANCER DISCOVERY, 2024, 14 (09) : 1675 - 1698
  • [42] Targeting KRAS G12C mutation in lung adenocarcinoma
    Rohatgi, Anjali
    Govindan, Ramaswamy
    LUNG CANCER, 2022, 165 : 28 - 33
  • [43] KRAS G12C inhibition and innate immune targeting
    Tani, Tetsuo
    Kitajima, Shunsuke
    Conway, Ella B.
    Knelson, Erik H.
    Barbie, David A.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (03) : 167 - 174
  • [44] Overcoming adaptive resistance to KRAS G12C inhibitors
    Adachi, Yuta
    Niitsu, Hiroaki
    Yamaguchi, Rui
    Ebi, Hiromichi
    CANCER SCIENCE, 2024, 115 : 110 - 110
  • [45] Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down
    Hobbs, G. Aaron
    Wittinghofer, Alfred
    Der, Channing J.
    CANCER CELL, 2016, 29 (03) : 251 - 253
  • [46] Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
    Burns, Timothy F.
    Dragnev, Konstantin
    Fujiwara, Yutaka
    Murciano-Goroff, Yonina R.
    Lee, Dae Ho
    Hollebecque, Antoine
    Koyama, Takafumi
    Cassier, Philippe
    Italiano, Antoine
    Heist, Rebecca S.
    Han, Ji-Youn
    Deming, Dustin
    Spira, Alexander
    Sabari, Joshua
    Chisamore, Michael J.
    Fink, Aaron
    Chen, Aaron
    Willard, Melinda D.
    Oxnard, Geoffrey R.
    Ammakkanavar, Natraj Reddy
    Pruthi, Aarohan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 137 - 138
  • [47] Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
    Burns, Timothy F.
    Dragnev, Konstantin H.
    Fujiwara, Yutaka
    Murciano-Goroff, Yonina R.
    Lee, Dae Ho
    Hollebecque, Antoine
    Koyama, Takafumi
    Cassier, Philippe Alexandre
    Italiano, Antoine
    Heist, Rebecca Suk
    Han, Ji-Youn
    Deming, Dustin A.
    Spira, Alexander I.
    Sabari, Joshua K.
    Chisamore, Michael Jon
    Fink, Aaron Alan
    Chen, Aaron
    Willard, Melinda D.
    Oxnard, Geoffrey R.
    Ammakkanavar, Natraj Reddy
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study
    Zhou, Qing
    Yang, Nong
    Zhao, Mingfang
    Huang, Dingzhi
    Zhao, Jun
    Yu, Yan
    Yuan, Ying
    Sun, Longhua
    Dong, Xiaorong
    Zhang, Tongmei
    Chu, Qian
    Li, Xingya
    Meng, Xiangjiao
    Wang, Huijuan
    Wang, Xiang
    Wu, Dongde
    Hu, Sheng
    Shan, Jinlu
    Liu, Lian
    Sun, Meili
    Zhang, Zhiye
    Zhu, Haibo
    Huang, Jingjing
    Huang, Mengna
    Cheng, Lingge
    Zhang, Sujie
    Zhou, Hui
    Wu, Yi-Long
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [49] Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC
    Pinto, L. Masfarre
    Rocha, P.
    Clave, S.
    Gorro, N. Navarro
    Sanchez, I.
    Giner, M.
    Lloret, A. Corbera
    Garcia, A. Taus
    Parreira, A. S. D. F. M.
    Paricio, B. Bellosillo
    Arriola, E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S145 - S146
  • [50] First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation
    Heymach, J.
    Kotecki, N.
    Prenen, H.
    Alonso, G.
    Lindsay, C. R.
    Barve, M.
    Thamer, C.
    Eigenbrod-Giese, S.
    Marotti, M. A.
    Van Lancker, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S468 - S468
12345